-
Mashup Score: 5Improved Molecular Classification Drives Tailored Treatment Approaches in Endometrial Cancer - 8 month(s) ago
Abdulrahman Sinno, MD, discusses the paradigm shift from a histology-based to molecular-based understanding of endometrial cancer and its impact on treatment outcomes.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Improved Molecular Classification Drives Tailored Treatment Approaches in Endometrial Cancer - 8 month(s) ago
Abdulrahman Sinno, MD, discusses the paradigm shift from a histology-based to molecular-based understanding of endometrial cancer and its impact on treatment outcomes.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Improved Molecular Classification Drives Tailored Treatment Approaches in Endometrial Cancer @SylvesterCancer #gyncsm #oncology https://t.co/oaTohc6vqs
-
-
Mashup Score: 0FDA Grants Priority Review to Pembrolizumab Plus Chemotherapy in Endometrial Cancer - 10 month(s) ago
The sBLA for pembrolizumab plus chemotherapy in endometrial cancer has been granted priority review by the FDA.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
The sBLA for pembrolizumab plus chemotherapy in endometrial cancer has been granted priority review by the FDA. @US_FDA #gyncsm #oncology https://t.co/8WQUuIdWOP
-
-
Mashup Score: 12Pembrolizumab Plus Lenvatinib Misses Both Survival End Points in Advanced, Recurrent Endometrial Cancer - 1 year(s) ago
The combination of pembrolizumab and lenvatinib failed to produce a statistically significant improvement in progression-free survival and overall survival vs platinum-based chemotherapy with carboplatin and paclitaxel as frontline therapy in patients with advanced or recurrent endometrial cancer whose disease in mismatch repair proficient/not microsatellite instability–high or mismatch repair deficient.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Pembrolizumab Plus Lenvatinib Misses Both Survival End Points in Advanced, Recurrent Endometrial Cancer #gyncsm #oncology https://t.co/7VbinBrfAh
-
-
Mashup Score: 12Pembrolizumab Plus Lenvatinib Misses Both Survival End Points in Advanced, Recurrent Endometrial Cancer - 1 year(s) ago
The combination of pembrolizumab and lenvatinib failed to produce a statistically significant improvement in progression-free survival and overall survival vs platinum-based chemotherapy with carboplatin and paclitaxel as frontline therapy in patients with advanced or recurrent endometrial cancer whose disease in mismatch repair proficient/not microsatellite instability–high or mismatch repair deficient.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Pembrolizumab Plus Lenvatinib Misses Both Survival End Points in Advanced, Recurrent Endometrial Cancer #gyncsm #oncology https://t.co/7VbinBrfAh
-
-
Mashup Score: 9Pembrolizumab Plus Lenvatinib Misses Both Survival End Points in Advanced, Recurrent Endometrial Cancer - 1 year(s) ago
The combination of pembrolizumab and lenvatinib failed to produce a statistically significant improvement in progression-free survival and overall survival vs platinum-based chemotherapy with carboplatin and paclitaxel as frontline therapy in patients with advanced or recurrent endometrial cancer whose disease in mismatch repair proficient/not microsatellite instability–high or mismatch repair deficient.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Pembrolizumab Plus Lenvatinib Misses Both Survival End Points in Advanced, Recurrent Endometrial Cancer #gyncsm #oncology https://t.co/7VbinBrfAh
-
-
Mashup Score: 1Cadonilimab Plus Chemo With or Without Bevacizumab Improves PFS in Recurrent or Metastatic Cervical Cancer - 1 year(s) ago
The frontline combination of cadonilimab and platinum-based chemotherapy with or without bevacizumab provided a progression-free survival benefit in patients with recurrent or metastatic cervical cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Cadonilimab Plus Chemo With or Without Bevacizumab Improves PFS in Recurrent or Metastatic Cervical Cancer #gyncsm #Oncology https://t.co/X9jnrHZvdz
-
-
Mashup Score: 1Cadonilimab Plus Chemo With or Without Bevacizumab Improves PFS in Recurrent or Metastatic Cervical Cancer - 1 year(s) ago
The frontline combination of cadonilimab and platinum-based chemotherapy with or without bevacizumab provided a progression-free survival benefit in patients with recurrent or metastatic cervical cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Cadonilimab Plus Chemo With or Without Bevacizumab Improves PFS in Recurrent or Metastatic Cervical Cancer #gyncsm #Oncology https://t.co/X9jnrHZvdz
-
-
Mashup Score: 4Dostarlimab Plus Chemo Provides OS Benefit in Primary Advanced or Recurrent Endometrial Cancer - 1 year(s) ago
The addition of dostarlimab to carboplatin plus paclitaxel followed by dostarlimab monotherapy significantly improved overall survival compared with placebo plus chemotherapy followed by placebo in adult patients with primary advanced or recurrent endometrial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Dostarlimab Plus Chemo Provides OS Benefit in Primary Advanced or Recurrent Endometrial Cancer #gyncsm #oncology https://t.co/5fbBbvaXF2
-
-
Mashup Score: 4Dostarlimab Plus Chemo Provides OS Benefit in Primary Advanced or Recurrent Endometrial Cancer - 1 year(s) ago
The addition of dostarlimab to carboplatin plus paclitaxel followed by dostarlimab monotherapy significantly improved overall survival compared with placebo plus chemotherapy followed by placebo in adult patients with primary advanced or recurrent endometrial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Dostarlimab Plus Chemo Provides OS Benefit in Primary Advanced or Recurrent Endometrial Cancer #gyncsm #oncology https://t.co/5fbBbvaXF2
-
Improved Molecular Classification Drives Tailored Treatment Approaches in Endometrial Cancer @SylvesterCancer #gyncsm #oncology https://t.co/oaTohc6vqs